For the execution of METHYLOMIC, the overall project is organised into seven Work Packages (WPs). WP1-5 form the scientific, clinical, and technological core; the remaining WPs (WP6-7) are essential integrating parts of the work plan to secure the project’s results, timelines, and short- and long-term impacts.
The main aim of this WP is to generate, improve and refine the algorithms capable of predicting response to biological treatment based on epigenetic DNA methylation markers that we found to discriminate responders from non-responders to treatment with 3 different mainstream biologicals in CD. Further, we also test the validity of this approach in Rheumatoid Arthritis (RA) and Psoriasis (PsO).
The overall aim of this WP is to develop a targeted methylation assay that will be useful in clinical use, that could work as a Companion Diagnostic. Such an assay will be used in a clinical trial in CD patients in WP3 that will put our idea to the test in clinical practice by the treating physicians by using an app device.
The overall aim of WP3 is to ensure the successful implementation and completion of the prospective randomised clinical trial for individualised therapy in CD patients.
The overall aim of this WP is to confirm the potential of DNA methylation markers for the prediction of biological therapy success in RA and PsO.
The overall aim of this work is to discover how DNA methylome-based biomarkers predict therapy response.
The overall aim of WP6 is to maximise the scientific, economic, and societal impacts of METHYLOMIC by implementing appropriate strategies for dissemination, exploitation and communication, and setting-up stakeholder workshops and cutting-edge trainings.
The overall aim of WP7 is to ensure that the project’s objectives are realised and that the project is implemented in compliance with the EC Grant Agreement and CA.